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IMPORTANCE This work quantifies the fatal burden of dementia associated with Alzheimer
disease in individuals with Down syndrome (DS).
OBJECTIVE To explore the association of dementia associated with Alzheimer disease
with mortality and examine factors associated with dementia in adults with DS.
DESIGN, SETTINGS AND PARTICIPANTS Prospective longitudinal study in a community setting
in England. Data collection beganMarch 29, 2012. Cases were censored on December 13,
2017. The potential sample consisted of all adults 36 years and older from the London Down
Syndrome Consortium cohort with 2 data times and dementia status recorded (N = 300);
6 withdrew from study, 28 were lost to follow-up, and 55 had a single data collection point
at time of analysis. The final sample consisted of 211 participants, with 503.92 person-years’
follow-up.
EXPOSURES Dementia status, age, sex, APOE genotype, level of intellectual disability, health
variables, and living situation.
MAIN OUTCOMES ANDMEASURES Crudemortality rates, time to death, and time to dementia
diagnosis with proportional hazards of predictors.
RESULTS Of the 211 participants, 96 were women (45.5%) and 66 (31.3%) had a clinical
dementia diagnosis. Twenty-seven participants (11 female; mean age at death, 56.74 years)
died during the study period. Seventy percent had dementia. Crudemortality rates for
individuals with dementia (1191.85 deaths per 10000 person-years; 95% CI, 1168.49-1215.21)
were 5 times higher than for those without (232.22 deaths per 10000 person-years; 95% CI,
227.67-236.77). For those with dementia, APOE ε4 carriers had a 7-fold increased risk of death
(hazard ratio [HR], 6.91; 95% CI, 1.756-27.195). For those without dementia, epilepsy with
onset after age 36 years was associated with mortality (HR, 9.66; 95% CI, 1.59-58.56). APOE
ε4 carriers (HR, 4.91; 95% CI, 2.53-9.56), adults with early-onset epilepsy (HR, 3.61; 95% CI,
1.12-11.60), multiple health comorbidities (HR, 1.956; 95% CI, 1.087-3.519), and those living
with family (HR, 2.14; 95% CI, 1.08-4.20) received significantly earlier dementia diagnoses.
CONCLUSIONS AND RELEVANCE Dementia was associated withmortality in 70%of older
adults with DS. APOE ε4 carriers and/or people with multiple comorbid health conditions
were at increased risk of dementia and death, highlighting the need for good health care.
For those who died without a dementia diagnosis, late-onset epilepsy was the only significant
factor associated with death, raising questions about potentially undiagnosed dementia cases
in this group.
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D ownsyndrome(DS)resultsfromtrisomyofchromosome21and is associatedwithmultiplehealthandcognitivecomorbidities includingcongenitalheartdefectsandin-
tellectualdisability(ID).1Fiftyyearsago, lifeexpectancyforthose
withDSwas just 10years,withcongenitalheartdefects respon-
sibleformostdeathswithinthefirstyear.2Medicaladvanceshave
since increasedmeansurvival to63.5years, yetpeoplewithDS
stilldieameanof13yearsbeforethosewithout.3Respiratorydis-
easesarenowthemost frequentlycitedprimarycausesofdeath
in adultswithDS,2,3with evidence that reducedmobility, poor
vision, and epilepsy are each associatedwith reduced survival
in lateryears.4However, this increasing lifeexpectancyinDShas
alsorevealedanexceptionalriskfordevelopingdementia,driven
bythenear-universalneuropathologyofAlzheimerdisease (AD)
byadulthood.5Understandinghowthisdiseaseburden is asso-
ciatedwithmortality in this aging population is of primary im-
portanceforprovidingappropriateprognostic information,care,
andresearchintopotentialADtreatmentsforthosebothwithand
without DS.
Alzheimer disease neuropathology inDS stems from trip-
lication of the amyloid precursor protein (APP) gene on chro-
mosome 21.6,7 Recent mouse model research has found that
triplication of other chromosome 21 genes can also increase
amyloid-β deposition and worsen cognitive deficits,8 al-
though these genes may also have different modulatory and
protective roles in AD progression, as suggested by differ-
ences between DS-AD and non-DS familial early-onset AD
caused by duplication of theAPP locus alone.9 The dementia
burden this causes in DS is striking: the mean age of demen-
tia diagnosis is 55 years,10 and as many as 88% of this popu-
lation can be expected to develop dementia by age 65 years.11
However, there is great variability in the age of dementia on-
set,with some individuals survivingpast age60yearswithno
clear signs of cognitive decline.12 Some dementia risk factors
seen in thenon-DSpopulation similarly play a role in the vari-
ability of onset in those with DS. For example, possession of
the apolipoprotein E (APOE) ε2 allele shows a protective in-
fluence, whereas APOE ε4 increases dementia risk.13 Demo-
graphic factors may also influence detection of cognitive de-
cline by caregivers; there is evidence that those who remain
livingwith their family are likely to receive a diagnosis earlier
than those in other living situations.10
Seizuredevelopment is closely linkedwithdementia inDS.
Forty-threepercent of thosewithout aprevioushistoryof epi-
lepsy develop seizures within a median of 2 years following
dementia diagnosis,withmost developing generalized tonic-
clonic seizures or myoclonic jerks as dementia progresses.14
Long-standing epilepsy, present before dementia diagnosis,
may shorten survival time after a diagnosis of dementia in in-
dividualswithDS,10 and there is also evidence that taking an-
tidementia mediation can extend survival.10
Although it has been reported that 20 timesmore people
with DS have dementia recorded as a contributory factor on
their death certificate than those without DS,15 further stud-
ies are required to quantify the association that dementia has
directlywithmortality risk in thosewithDS, aswell as explor-
ing factors thatmaymodifymortality anddementia risk in this
population. Better information about factors associatedwith
dementia onset and prognosis will also support the develop-
ment of clinical trials of treatments.
Thisstudyaimedtoexaminetheeffectofdementiaoncrude
mortality rates (CMRs) ina large, representative cohortofolder
individualswithDS intheUnitedKingdom.Secondaryanalyses
were used to evaluate the influence of additional health and
demographic factorsonageatdeathandatdementiadiagnosis.
Methods
Study Design and Setting
Data were acquired as part of a large, prospective longitudi-
nal studyofcognitionandhealth inadultswithDS in theUnited
Kingdom.16 Ethical approval was secured from the North-
WestWalesResearchEthicsCommittee (13/WA/0194). Partici-
pation in theprimary studywas open to all adultswithDS, re-
gardlessof capacity to consent.Capacitywasassessed for each
participantat each time, andwritten informedconsentwasob-
tained from all those who were able. A consultee (typically a
family member or paid carer) was appointed for individuals
without capacity. The consultee was asked to sign a form to
indicate their decision about the individual’s inclusion based
on their knowledge of the individual and their wishes, in ac-
cordance with the UKMental Capacity Act 2005.
Participants
ParticipantswererecruitedfromDSsupportgroups,carehomes,
existingparticipantdatabases,andNationalHealthServicessites
in England. Down syndrome statuswas confirmed genetically
wherepossible (n = 193of211successfullykaryotyped).Tobeeli-
gible for inclusion, participantswere required to be 36 years or
older at study entry, tohave at least 2data points (mean length
offollow-up,28.66months;range,1-65months).andtohavetheir
clinical dementia status known to the informant.
Data Sources/Measurements
Data forall variableswerecollectedaspartofaprospective, lon-
gitudinal study.Medical historyanddemographicdetailswere
acquired through a semistructured interviewwith a carerwho
knew the participant well. APOE genotype was confirmed via
bloodorsalivasampleusingaThermoFisherScientificTaqman
assayforsingle-nucleotidepolymorphismsrs7412andrs429358.
Key Points
Question How does dementia status influencemortality in people
with Down syndrome?
Findings In a longitudinal study including 211 adults with Down
syndrome 36 years and older, 27 people died during follow-up
(mean, 28; range, 1-65months), and dementia was the proximate
cause of death in 70% of cases. Crudemortality rates were 5 times
higher in those with dementia than those without.
Meaning Nearly all older adults with Down syndrome now have
dementia when they die, making this a vital population for
researching disease progression, modifying factors, and potential
treatments.
Association of Alzheimer DiseaseWith Mortality Rates Among Older Adults With Down Syndrome Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology February 2019 Volume 76, Number 2 153
Downloaded From: https://jamanetwork.com/ by a Nanyang Technological University User  on 04/11/2019
Statistics
Crude mortality rates were calculated using total months of
follow-up time for thewhole sample andsplit bydementia sta-
tus.TheKaplan-Meiermethodwasusedtoexaminesurvivaltime
for thosewithandwithoutadementiadiagnosis.Toexplore fac-
torspredictingmortality,Coxproportionalhazardmodelswere
computedseparatelyforthosewithandwithoutdementia,using
ageatexit (ordeath)as thetimevariable.Eachpredictorvariable
wasentered intoan independentpredictormodel in the first in-
stance.Variablessignificantlyassociatedwithmortalitywerethen
combined in a finalmodel, using the entermethod. To explore
factors associated with diagnosis of dementia, Cox regression
modelswere computedusing the samepredictor variables but
using age at diagnosis/exit from study as the timing variable.
Variables
Time-to-event analyseswere computed for death and demen-
tiadiagnosis.Dementiastatuswasobtainedthroughcarerreport,
based on independent clinical diagnosis by participants’ regu-
lar clinicians after comprehensive clinical assessment. In the
UnitedKingdom, individualswithDSare typicallydiagnosedas
havingdementiaafterspecialistassessment inIDservices; these
expert clinical diagnoses have been shown to be reliable and
valid.17Toconfirmdementia status, 2 IDpsychiatrists indepen-
dently revieweddementia symptoms for a sampleof individu-
alsblindtooriginalclinicaldiagnosesusing itemsmappingto In-
ternationalStatisticalClassificationofDiseasesandRelatedHealth
Problems,TenthRevisionandDiagnostic andStatisticalManual
ofMentalDisorders (FourthEdition)dementia criteria fromthe
structured interview of the Cambridge Examination ofMental
DisordersofOlderPeopleWithDownSyndromeandOthersWith
IntellectualDisabilities.18Thepresenceof significant cognitive
decline owing to dementia was confirmed in 86% of individu-
alsandtheremaining14%showingsomedegreeofcognitivede-
cline(possibledementia)(totaln = 36).Becausedementiaisapro-
gressivediseasewithaprodromalperiodspanningmanyyears,
individualsdiagnosedduringfollow-upwere includedinthede-
mentia group. Time variables included length inmonths from
studyentrytoexit forCMRcalculationsandage inyearsatevent
(deathordementiadiagnosis)orexitforhazardratiocalculations.
The latestdatacollectionpointwasusedas theexitdate forcen-
sored cases. Caseswere censored onDecember 13, 2017.
Predementia level of ID was obtained via carer report of
the participants’ peak level of functioning, based on Interna-
tional Statistical Classification of Diseases and Related Health
Problems,TenthRevision characteristics ofmild,moderate, se-
vere, or profound ID. Categories were collapsed to produce a
binary variable (mild/moderate vs severe/profound).
For theAPOEvariable,participantsweregroupedforanaly-
sis such that thosewith2ε3alleles formedthe referencegroup,
thosewith1or2ε2allelesformedasecondgroup,andthosewith
1 or 2 ε4 alleles formed the third group. Participantswith ε2:ε4
genotype(n = 5)wereexcludedfromAPOEanalysesowingtothe
opposing effects of alleles ε2 and ε4.
Living situation split those living with family from those
in other living situations including supported accommoda-
tion, care homes, and residential homes.Additional factors of
interest included sex, presence of early-onset (before age 20
years) and late-onset (older than 36 years) epilepsy, hypothy-
roidism, congenital heart defects, cataracts, dementia medi-
cation, antipsychotic medication, obesity (defined as having
a bodymass index greater than 30 [calculated asweight in ki-
lograms divided by height in meters squared]), and a binary
multimorbidity score (0 = noneor 1 comorbid condition; 1 = 2
or more conditions). Health conditions included in this score
and the list of drugs counted in the medication variables are
listed in the eMethods of the Supplement.
Results
Sample
Two hundred eleven people (96women) were included in the
final sample, giving 503.92 person-years of follow-up: 344.50
person-years fromthosewithoutdementia and 159.42person-
years from those who received a clinical dementia diagnosis
(n = 66). Themean (SD) age of dementia diagnosis overall was
51.98(7.09)years (n = 65,datamissingfrom1participant);50.83
(5.72) years for women; and 53.41 (8.38) years formen. Table 1
displays participant characteristics by dementia status.
CrudeMortality Rates
Figure 1 shows the Kaplan-Meier survival function for those
with andwithout a diagnosis of dementia; estimatedmedian
survival times were 67 and 72 years, respectively. Twenty-
seven participants (11 women) died during the follow-up pe-
riod. The median age at death was 57 years (57 years for men
and54years forwomen).Nineteenparticipants (70.37%) had
a clinical diagnosis of dementia, 9 of whom were women
(47.37%).Tenmen (62.5%)and9women (81.8%)whodiedhad
adiagnosis of dementia. Themedianage at deathwas 57years
for those without dementia and 55 years for those with de-
mentia. During the follow-up period, 28.78%of the dementia
group (n = 19) died comparedwith 5.52%of thosewithoutde-
mentia (n = 8). The CMR across thewhole samplewas 535.80
deaths per 10000 person-years (95% CI, 529.30-550.30); for
thosewith dementia, the CMRwas 1191.85 deaths per 10000
person-years (95% CI, 1168.49-1215.21); and for those with-
out a dementia diagnosis, the CMR was 232.22 deaths per
10000 person-years (95% CI, 227.67-236.77).
Of the 8 participantswhodiedwithout a clinical diagnosis
ofdementia, 2had late-onset epilepsy, and1was reported tobe
showingearlysignsofcognitivedecline.Onediedataged50years
ofapossibleunderlyingheartcondition;2diedofrespiratorydis-
easeswithnosignsofdeclineatage63yearsand73years, respec-
tively; and for 2 participants the cause of deathwas unknown.
Factors AssociatedWithMortality by Dementia Status
Table 2 shows theCox regression results for each independent
factorsplitbydementiastatusandthefinalcombinedmodel for
thosewithdementia. For individualswithout adementiadiag-
nosis, individualCoxregressionsrevealedthatlate-onsetepilepsy
was theonlyvariable associatedwithmortality,withanear 10-
fold increase inrisk.Forthosewithaclinicaldiagnosisofdemen-
tia,APOE genotype,multimorbidity, early-onset epilepsy, and
dementiamedicationstatuswereall significantly independently
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associatedwithmortality, such thatpresenceof 1ormoreAPOE
ε4 alleles, 2 ormore health conditions, or early-onset epilepsy
eachwere associatedwith increasedmortality risk, and taking
antidementia medication was associated with decreased risk.
Whenentered into a combinedmodel, including all significant
factors,APOE genotypewas the only factor tomaintain an as-
sociationat theP < .05 level. Thepresenceof at least 1APOEε4
allelewasassociatedwith increasedmortality risknearly7-fold
comparedwith thosewith2APOEε3alleles. Inour sample, sex
was not statistically significantly associatedwithmortality for
thosewith orwithout dementia.
Factors AssociatedWith Age at Dementia Diagnosis
Sex (women diagnosed earlier), APOE genotype, multimor-
bidity, early-onset epilepsy, and living situationwere found to
be independently associatedwith age at dementia diagnosis.
All but sex remained significantly associated in the com-
bined model (Table 3, with hazard functions in Figure 2).
Figure 1. Cumulative Survival by Dementia Status
0
No. at risk
35
62
107
66
145
55
8
4
65
0
0
75
1.0
0.8
Cu
m
ul
at
iv
e 
Su
rv
iv
al
Age, y
0.6
0.4
0.2
45
29
107
Dementia
Dementia
No dementia
No dementia
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Table 1. Participant Demographics by Dementia Status
Demographic
No. (%)
No Dementia Dementia
Total No. (%) 145 (68.72) 66 (31.28)
Female 60 (41.4) 36 (54.5)
Level of ID
Mild/moderate 119 (82.1) 50 (75.8)
Severe/profound 25 (17.2) 10 (15.2)
Missing data 1 (0.7) 6 (9.1)
Living situation
Home with family/partner 31 (21.4) 46 (69.7)
Supported living/care home 113 (77.9) 19 (28.8)
Missing 1 (0.7) 1 (1.5)
Age at entry, mean (SD) [range], y 47.84 (7.29) [36-72] 53.62 (6.94) [38-67]
Age at exit, mean (SD) [range], y 50.23 (7.30) [38-74] 56.05 (7.00) [40-70]
Length of follow-up, mean (SD) [range] mo 28.51 (10.65) [3.0-65.0] 28.98 (12.65) [1.0-55.0]
BMI, mean (SD) [range] 30.16 (6.99) [17.78-56.80 ] 30.79 (7.01) [20.40-54.00]
Obesity (BMI >30) 56 (47.06) 25 (53.19)
Missing data, No. 26 19
Late-onset epilepsy 7 (4.8) 19 (28.8)
Receiving antiepilepsy medication 5 (71.42) 14 (73.68)
Missing data, No. 1 2
Early-onset epilepsy 4 (2.8) 4 (6.1)
Receiving antiepilepsy medication 4 (100) 4 (100)
Receiving antipsychotics (all atypical) 15 (10.34) 10 (15.15)
Hypothyroidism 63 (43.4) 26 (39.4)
Cataracts 32 (22.1) 27 (40.9)
Congenital heart condition 30 (20.7) 7 (10.6)
APOE genotype
ε2:ε2 or ε2:ε3 21 (14.5) 8 (12.1)
ε3:ε3 89 (61.4) 31 (47.0)
ε3:ε4 or ε4:ε4 25 (17.3) 20 (30.3)
ε2:ε4 3 (2.1) 2 (3.0)
Missing data 7 (4.8) 5 (7.6)
≥2 comorbid health conditions 76 (52.4) 34 (51.5)
Receiving antidementia medication NA 33 (50.0)
Abbreviations: APOE, apolipoprotein
E; BMI, bodymass index (calculated
as weight in kilograms divided by
height in meters squared); NA, not
applicable.
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Increased risk fordevelopingdementiawas seen for those car-
rying at least 1APOE ε4 allele (5-fold increase comparedwith
2 APOE ε3 alleles), having 2 or more comorbid health condi-
tions (2-fold increase), and having early-onset epilepsy (near
4-fold increase). Those living with family were diagnosed at
an earlier age. In this sample, carrying an APOE ε2 allele was
not found to be protective comparedwith those with 2APOE
ε3 alleles (P = .36).
Discussion
This studyexamined the effect of dementiadiagnosis onmor-
tality in a representative cohort of adults with DS in England.
Dementia was the proximate cause of death in 70% of our
sample overall: 10men (62.5%) and 9women (81.8%) had de-
mentia when they died. At least 3 of 8 participants who died
without a dementia diagnosis showed signs of cognitive de-
clineand/or seizures; thus, thisproportionmaybeevenhigher.
These results compare strikinglywithmortality statistics
for England and Wales: dementia of any subtype is men-
tioned in17.5%ofdeathcertificates for those65yearsandolder;
andolder than80years, dementia is the leadingcauseofdeath
for 14% and 22% ofmale and female deaths respectively.19,20
In our sample, crudemortality was increased 5-fold for those
withdementia (CMRwithdementia, 1191.85deathsper 10000
person-years vs CMR without dementia, 232.22 deaths per
10000person-years), giving a similarmortality rate for those
Table 2. Model Coefficients of Factors AssociatedWithMortality in AdultsWith DS
Variable β Coefficient (SE) df P Value Hazard Ratio (95% CI)
Adults with DS without dementia
Independent factors
Sex 0.8 (0.820) 1 .33 2.23 (0.45-1.11)
Level of ID −3.28 (5.245) 1 .53 0.04 (0-1102.73)
Multimorbidity status 1.12 (0.767) 1 .14 3.06 (0.68-13.77)
APOE genotype 2 .69
APOE group 2 vs group 3 −0.94 (1.097) 1 .39 0.39 (0.045-3.35)
APOE group 4 vs group 3 −12.49 (862.96) 1 .99 0
Early-onset epilepsy −3.02 (44.05) 1 .95 0.049 (0-1.54 × 1036)
Late-onset epilepsy 2.27 (0.920) 1 .01 9.66 (1.59-58.56)
Congenital heart defects 0.29 (0.856) 1 .73 1.34 (0.25-7.17)
Antipsychotic medication −0.07 (1.085) 1 .95 0.93 (0.11-7.82)
Obesity (BMI >30) 0.031 (0.925) 1 .97 1.03 (0.17-6.32)
Hypothyroidism 0.61 (0.721) 1 .40 1.84 (0.45-7.56)
Cataracts 0.06 (0.740) 1 .94 1.06 (0.25-4.52)
Adults with DS and dementia
Independent factors
Sex −0.32 (0.495) 1 .52 0.73 (0.28-1.91)
Level of ID −0.12 (0.772) 1 .89 0.90 (0.20-4.08)
Multimorbidity status 1.24 (0.530) 1 .02 (1.23-9.80)
APOE genotype 2 .01
APOE group 2 vs group 3 −0.28 (0.809) 1 .73 0.75 (0.15-3.68)
APOE group 4 vs group 3 1.75 (0.637) 1 .006 5.74 (1.65-19.99)
Early-onset epilepsy 1.87 (0.805) 1 .02 6.50 (1.34-31.47)
Late-onset epilepsy 0.59 (0.490) 1 .23 1.80 (0.69-4.69)
Congenital heart defects −0.45 (1.036) 1 .67 0.64 (0.08-4.87)
Antipsychotic medication 0.532 (0.586) 1 .36 1.70 (0.54-5.37)
Obesity (BMI >30) −1.078 (0.692) 1 .12 0.34 (0.09-1.32)
Hypothyroidism −0.06 (0.506) 1 .90 0.94 (0.35-2.53)
Cataracts 0.44 (0.484) 1 .36 1.55 (0.60-4.01)
Dementia medication status −1.47 (0.560) 1 .009 0.23 (0.08-0.69)
Final model
Multimorbidity status 1.27 (0.704) 1 .07 3.57 (0.90-14.20)
APOE genotype 2 .009
APOE group 2 vs 3 −0.73 (0.857) 1 .39 0.48 (0.09-2.58)
APOE group 4 vs 3 1.93 (0.699) 1 .006 6.91 (1.76-27.20)
Early-onset epilepsy 1.57 (0.896) 1 .08 4.79(0.83-27.69)
Dementia medication status −0.97 (0.689 1 .16 0.38 (0.10-1.46)
Abbreviations: APOE, apolipoprotein
E; BMI, bodymass index (calculated
as weight in kilograms divided by
height in meters squared);
ID, intellectual disability.
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withdementia to that reported forADdementia in thenon-DS
population (1070 deaths per 10000 person-years).21
In our sample, we found no clear differences inmortality
betweenmen and women, matching previous work showing
similaragesatdeath inmenandwomenwithDS.2Womenwere
diagnosed as having dementia up to 3 years earlier thanmen.
This pattern has been previously reported in adults with DS
intheUnitedKingdom10;however,our findingsonlyheldwhen
sexwasconsideredasan independent factor. In thefinalmodel,
includingAPOEgenotype,multimorbidity, living situationand
early-onset epilepsy, the influence of sex on dementia diag-
nosis was lost.
SeizuresareacommonfeatureofADinthosewithandwith-
outDS, occurring in aquarter of patientswithoutDSwithAD22
and40%ofpatientswithDSandAD.14However, late-onsetepi-
lepsywas also noted in 7 people (4.8%)without a dementia di-
agnosis inour study, increasingmortality risk 10-fold.For those
withoutdementia, late-onsetepilepsywas theonly factorasso-
ciatedwithmortality.Thisraisesthequestionofwhetherseizures
can begin in the absence of other features of dementia in indi-
viduals with DS orwhether these 7 individuals had significant
ADpathologyandneurological symptomsbuthadyet toreceive
a formal dementia diagnosis.While preexisting ID canmake it
challengingfordeclinetobeidentifiedinthispopulation,detailed
clinical assessmentshavebeen found tobe robust andvalid for
thosewithDS,17 andarangeofsensitivecognitivebatterieshave
beendevelopedwithin thepast 10years.16,23-25Baselineassess-
mentscompletedinearlyadulthoodcanhelptoserveaseachin-
dividual’s reference point, allowing decline to be identified on
an individual level in this highly variable population.26
For peoplewithDSanddementia, carrying at least 1APOE
ε4 allele was associated with increased mortality risk 7-fold.
These results suggest peoplewithDSmaybeparticularly vul-
nerable to theeffectsofAPOEε4becauseAPOEε4carrierswith
AD in thenon-DSpopulation show little difference to noncar-
rierswithAD indiseaseprogressionormortality.27,28Ourdata
confirm some of the other associations with mortality previ-
ouslyobserved, including thedeleteriouseffectofepilepsyand
the potentially beneficial effect of currently available medi-
cation such as acetyl-choline esterase inhibitors.29 However,
otherassociationswerenotobserved:antipsychoticshavebeen
found to doublemortality risk in peoplewith dementia in the
non-DS population,30 yet in our sample we did not find a sta-
tistically significantassociationbetweenantipsychoticuseand
death in thosewithorwithoutdementia. Similarly, obesityhad
nodiscernible associationwithdeathordementiaonset in this
study. Our data are from a comparatively small group, with a
maximumfollow-uptimeof65months.Further researchusing
larger samples over longer periods of timewould be valuable
to clarify whether these reflect genuine differences in risk in
the DS population or simply reflect a lack of power for identi-
fying multiple risk factors in this sample.
APOE ε4 genotype, early-onset epilepsy, multimorbidity,
and living with family were all associated with earlier
dementia diagnoses. Previous studies have shown that
APOE genotype influences dementia risk in DS in much the
same way as in the non-DS population. Similarly, epilepsy
has been found to increase risk of AD in the general popula-
tion, with adults with epilepsy younger than 65 years nearly
40 times more likely and those older than 65 years nearly 7
times more likely to be diagnosed as having AD.31 Aside from
known vascular risk factors, combined health comorbidities
may also increase dementia risk in those without DS, sug-
gesting a role for poor general health in dementia risk.32
Table 3. Model Coefficients for Factors AssociatedWith Dementia
Variable β Coefficient (SE) df P Value Hazard Ratio (95% CI)
Independent factors associated with dementia
Sex (women vs men) −0.581 (0.253) 1 .02 0.56 (0.34-0.92)
Level of ID 0.265 (0.352) 1 .45 1.30 (0.65-2.60)
Early-onset epilepsy 1.716 (0.532) 1 .001 5.56 (1.96-15.79)
Multimorbidity status 0.531 (0.254) 1 .04 1.70 (1.03-2.80)
Congenital heart defect −0.294 (0.402 1 .46 0.75 (0.34-1.64)
APOE genotype 2 <.001
APOE group 2 vs group 3 −0.245 (0.4) 1 .54 0.78 (0.36-1.71)
APOE group 4 vs group 3 1.56 (0.324) 1 <.001 4.76 (2.52-8.97)
Cataracts 0.339 (0.253) 1 .18 1.40 (0.85-2.30)
Living situation (family vs other) 1.053 (0.29) 1 <.001 2.87 (1.62-5.06)
Antipsychotic medication 0.061 (0.346) 1 .86 1.06 (0.54-2.10)
Obesity (BMI >30) 0.308 (0.298) 1 .30 1.36 (0.76-2.44)
Hypothyroidism 0.133 (0.255) 1 .60 1.14 (0.69-1.88)
Final model
Sex (women vs men) 0.391 (0.283) 1 .17 1.48 (0.85-2.58)
Living situation (family vs other) 0.758 (0.346) 1 .03 2.14 (1.08-4.20)
Early-onset epilepsy 1.284 (0.596) 1 .03 3.61 (1.12-11.60)
Multimorbidity status 0.671 (0.3) 1 .03 1.96 (1.09-3.52)
APOE genotype 2 <.001
APOE group 2 vs group 3 −0.543 (0.433) 1 .21 0.58 (0.25-1.36)
APOE group 4 vs group 3 1.593 (0.339) 1 <.001 4.92 (2.53-9.56)
Abbreviations: APOE, apolipoprotein
E; BMI, bodymass index (calculated
as weight in kilograms divided by
height in meters squared);
ID, intellectual disability.
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A further explanation could be that increased interaction
with health care services for those with multiple health con-
ditions and increased awareness of change for those living
with family may make these groups more likely to receive a
dementia assessment and subsequent diagnosis rather than
increasing risk of dementia per se.
Becausemultimorbiditywasassociatedwith increasedde-
mentia risk andmortality in thosewho received dementia di-
agnoses, our results also highlight the need for effective rec-
ognitionand treatmentof commonhealthcomorbidities inDS.
Individualswith IDexperiencesignificanthealth inequalities,33
and evidence suggests that incentivizing general practition-
ers tooffer comprehensive IDhealthchecks increases thenum-
ber of specific health assessments completed and may thus
reduce saidhealth inequalities.34 Given that several of the co-
morbiditieswe includedare treatable, suchhealthcheckscould
have longer-term positive effects than have previously been
assessed.
Limitations
Our data were collected as part of a prospective, longitudinal
study of adults with DS, providing extensive health informa-
tion and cognitive assessments for the individuals. While
our sample is large for a study of such detail, we acknowl-
edge that the numbers included are relatively small for an
epidemiologic study. Health data were collected via infor-
mant report, which may be influenced by reporter bias, their
memory, and the relationship between the informer and the
individual with Down syndrome.
Conclusions
Our study shows that most adults with DS now have demen-
tia when they die and are affected by some of the same fac-
tors associatedwith dementia (such asAPOE genotype) aswe
see in the non-DS population. These findings support the ur-
gent need for clinical trials of treatments to prevent or delay
dementia in thosewith DS. Finally, we hope that our findings
can improveclinical careby identifying factors associatedwith
increased risk for dementia andmortality risk in this popula-
tion, suggesting the potentially beneficial effects of existing
medication options and helping clinicians provide prognos-
tic information for their patients with DS.
Figure 2. Proportional Hazards of Dementia Predictors
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